• A single health-system, retrospective cohort study using data from electronic medical records of patients with NVAF and a BMI ≥50 kg/m2 who initiated apixaban or rivaroxaban between January 2013 and September 2019*
  • The patients were followed from the date of initiation to the earliest adverse outcome, which included discontinuation of medication, death, or the end of the study period on September 30, 2020